GNI GroupGNIIF 84 PB Ratio is 2.74 as of Jun. 29, 2026, which is 40% below its 10-year median of 4.60. GuruFocus rates GNIIF with a GF Score™ of 84/100 and a GF Value™ of $17.11. The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, GNI Group ranks better than 50.81% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), GNI Group's share price is $15.50. GNI Group's Book Value per Share for the quarter that ended in Mar. 2026 was $5.66. Hence, GNI Group's PB Ratio of today is 2.74.
Good Sign:
GNI Group Ltd stock PB Ratio (=2.8) is close to 1-year low of 2.59.
The historical rank and industry rank for GNI Group's PB Ratio or its related term are showing as below:
GNIIF'
s PB Ratio Range Over the Past 10 Years
Min: 2.28 Med: 4.6 Max: 32.13
Current: 2.8
During the past 13 years, GNI Group's highest PB Ratio was 32.13. The lowest was 2.28. And the median was 4.60.
GNIIF's PB Ratio is ranked better than 50.81% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs GNIIF: 2.80
During the past 12 months, GNI Group's average Book Value Per Share Growth Rate was 32.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 23.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GNI Group was 55.20% per year. The lowest was -32.20% per year. And the median was 24.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GNI Group PB Ratio Related Terms
GNI Group PB Ratio Historical Data
* Premium members only.
The historical data trend for GNI Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GNI Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GNI Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GNI Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where GNI Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
GNI Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GNI Group (GNIIF) has a PB Ratio of 2.74 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GNI Group and its competitors. This is 40% below median its historical median of 4.60. Over the past decade, GNI Group's PB Ratio has ranged from 2.28 to 32.13. According to the industry distribution chart, GNI Group ranks #606 out of 1232 companies in the Biotechnology industry, placing it in the top 49.2%.
Is GNI Group's PB Ratio too high?
GNI Group's current PB Ratio of 2.74 is 40% below median its 10-year median of 4.60. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 32.13. The Biotechnology industry median PB Ratio is 2.84. GNI Group's value of 2.74 is 3.4% below this industry median. Based on the distribution chart, GNI Group ranks #606 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GNI Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does GNI Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #606 out of 1232 companies for PB Ratio. This puts GNI Group in the upper half of its industry. The industry median PB Ratio is 2.84. GNI Group's value of 2.74 is 3.4% below this benchmark. Historically, GNI Group's own PB Ratio has ranged from 2.28 to 32.13 over the past decade. While the company's 10-year median is 4.60 vs. the industry median of 2.84, GNI Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GNI Group's current PB Ratio of 2.74 is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GNI Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GNI Group's current PB Ratio is 2.74, which is 40% below median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
GNI Group (GNIIF) has a current PB Ratio of 2.74. The stock's GF Value™ is $17.11, compared to a current price of $15.50 — trading 9.4% below its estimated fair value. The current PB Ratio is 2.74, which is 40% below median its 10-year median of 4.60 and 3.4% below the Biotechnology industry median of 2.84. GNI Group's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GNI Group (GNIIF), the current PB Ratio is 2.74 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GNI Group (GNIIF) Overvalued in 2026?
Based on GuruFocus' analysis, GNI Group stock appears to be undervalued.
The current stock price of $15.50 is trading 9.4% below its estimated GF Value™ of $17.11.
Key valuation signals for GNIIF:
PB Ratio: 2.74 (40% below median its 10-year median of 4.60)
GF Value™: $17.11 vs. price of $15.50 (9.4% below fair value)
Industry Position: 3.4% below the Biotechnology median (#606 of 1232)
No single metric tells the full story. See the GNIIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
84GF Score
Get the complete analysis for GNIIF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNIIF has been successfully added to your 
